James D. Fisher

James D. Fisher

Auto-generated profile, based on publicly available information

James D. Fisher

Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
JFJames D. Fisher
James D. Fisher
WZWensheng Zhang
Wensheng Zhang
SBStephen C. Balmert
Stephen C. Balmert
AAAli M. Aral
Ali M. Aral
AAAbhinav P. Acharya
Abhinav P. Acharya
SLSteven R. Little
Steven R. Little
Vascularized composite allotransplantation (VCA) encompasses face and limb transplantation, but as with organ transplantation, it requires lifelong regimens of immunosuppressive drugs to prevent rejection. To achieve donor-specific immune tolerance and reduce the need for systemic immunosuppression, we developed a synthetic drug delivery system that mimics a strategy our bodies naturally use to recruit regulatory T cells (Treg) to suppress inflammation. Specifically, a microparticle-based system engineered to release the Treg-recruiting chemokine CCL22 was used in a rodent hindlimb VCA model. These “Recruitment-MP” prolonged hindlimb allograft survival indefinitely (>200 days) and promoted donor-specific tolerance. Recruitment-MP treatment enriched Treg populations in allograft skin and draining lymph nodes and enhanced Treg function without affecting the proliferative capacity of conventional T cells. With implications for clinical translation, synthetic human CCL22 induced preferential migration of human Treg in vitro. Collectively, these results suggest that Recruitment-MP promote donor-specific immune tolerance via local enrichment of suppressive Treg.